AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

AstraZeneca's shares plummeted around 7% after reports emerged of potential $400 billion merger talks with U.S. pharmaceutical giant Bristol Myers Squibb. The U.K.'s largest drugmaker was in intriguing discussions with its American peer, which could potentially elevate both companies' value to a staggering $400 billion, according to the Financial Times.

However, neither company provided immediate comment. The proposed merger, if finalized, would rank among the largest pharmaceutical deals in history. AstraZeneca's shares, which had dropped 6.2% in early morning trading, impacted the U.K.'s blue-chip index FTSE 100, which remained largely unchanged. At the time of writing, AstraZeneca's market capitalization stood at $264 billion, a figure that had been on a steady rise over the past decade since CEO Pascal Soriot assumed leadership in 2012 amidst the development of a robust pipeline of new drugs.

The company aims to achieve $80 billion in sales by 2030, a significant increase from last year's $58.7 billion. Meanwhile, Bristol Myers Squibb's market capitalization is approximately $133 billion. Despite the absence of detailed information and the possibility that the deal may not materialize, analysts expressed confusion over the news.

Jefferies analysts, in particular, expressed bewilderment, stating, "Given the strength of AZ's growth and innovation profile, we are a bit perplexed." While financial accretion might appear attractive and increased cash generation could potentially bolster research and development, analysts questioned the need for such 'financial engineering,' especially considering that AstraZeneca might not require it.